Pomalidomide(pomalyst) 4MG cap
Ended Awarded
- Contract number
- 36C24526N0285
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $16,422
Award facts
- Contract value 100% obligated
- $16,421.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer, received a delivery order valued at $16,421.95 for Pomalidomide (Pomalyst) 4mg capsules from Veterans Integrated Service Network 5 (VISN 5), a civilian component of the Department of Veterans Affairs. This firm fixed-price contract, awarded on February 3, 2026, with an ultimate completion date of February 6, 2026, carries no set-aside designation. The order will be fulfilled from the company's Lawrenceville, New Jersey facility with delivery to Memphis, Tennessee, and represents a call against Bristol-Myers Squibb's Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs, which carries a substantial ceiling value of $12.28 billion and extends through April 30, 2029.
This delivery order supports the Veterans Health Administration's mission to provide advanced oncology treatments to eligible veterans. Pomalidomide is an immunomodulatory agent used primarily in the treatment of multiple myeloma and other hematologic malignancies. The award reflects the VA's sustained procurement relationship with Bristol-Myers Squibb for specialized pharmaceutical therapies, with over fifty documented delivery orders issued through the FSS contract since 2022. This particular order is one of numerous calls placed by various VISNs across the VA healthcare system to ensure adequate supply of critical cancer medications that represent the current standard of care in oncology treatment for the veteran population.
Quick answers
Who was awarded contract 36C24526N0285?
36C24526N0285 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 3, 2026.
How much is contract 36C24526N0285 worth?
The government has obligated $16,422 on 36C24526N0285.
Is contract 36C24526N0285 an order under another contract?
Yes. 36C24526N0285 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0285 competed?
The extent of competition for 36C24526N0285 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award